JP2009519011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519011A5 JP2009519011A5 JP2008542829A JP2008542829A JP2009519011A5 JP 2009519011 A5 JP2009519011 A5 JP 2009519011A5 JP 2008542829 A JP2008542829 A JP 2008542829A JP 2008542829 A JP2008542829 A JP 2008542829A JP 2009519011 A5 JP2009519011 A5 JP 2009519011A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom4
- tar2h
- dom7r
- dab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000178 monomer Substances 0.000 claims 45
- 239000003446 ligand Substances 0.000 claims 27
- 102000010932 Interleukin-1 receptor type 1 Human genes 0.000 claims 19
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102000000589 Interleukin-1 Human genes 0.000 claims 10
- 108010002352 Interleukin-1 Proteins 0.000 claims 10
- 101100268517 Mus musculus Serpina1d gene Proteins 0.000 claims 9
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 8
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 8
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 8
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000007562 Serum Albumin Human genes 0.000 claims 6
- 108010071390 Serum Albumin Proteins 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 239000006199 nebulizer Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 4
- 230000015556 catabolic process Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 125000003827 glycol group Chemical group 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 1
- 208000034423 Delivery Diseases 0.000 claims 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 108010057368 Interleukin-1 Type I Receptors Proteins 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 1
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- -1 inhaler Substances 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009677 vaginal delivery Effects 0.000 claims 1
- 238000013389 whole blood assay Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74206205P | 2005-12-01 | 2005-12-01 | |
| PCT/GB2006/004471 WO2007063308A2 (en) | 2005-12-01 | 2006-11-30 | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519011A JP2009519011A (ja) | 2009-05-14 |
| JP2009519011A5 true JP2009519011A5 (enExample) | 2010-01-07 |
Family
ID=37885775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542829A Pending JP2009519011A (ja) | 2005-12-01 | 2006-11-30 | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090155283A1 (enExample) |
| EP (1) | EP1957536A2 (enExample) |
| JP (1) | JP2009519011A (enExample) |
| KR (1) | KR20080077238A (enExample) |
| CN (1) | CN101454344A (enExample) |
| AU (1) | AU2006321364B2 (enExample) |
| BR (1) | BRPI0619225A2 (enExample) |
| CA (1) | CA2632866A1 (enExample) |
| CR (1) | CR10022A (enExample) |
| EA (1) | EA200801170A1 (enExample) |
| MA (1) | MA30300B1 (enExample) |
| NO (1) | NO20082215L (enExample) |
| TW (1) | TW200730539A (enExample) |
| WO (1) | WO2007063308A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02012867A (es) | 2000-06-29 | 2003-09-05 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos. |
| US8324350B2 (en) | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
| CA2683791A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains & antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| CN102224169A (zh) * | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| BRPI1008014A2 (pt) * | 2009-02-19 | 2016-10-04 | Glaxo Group Ltd | domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro |
| MX2012000765A (es) * | 2009-07-16 | 2012-02-13 | Glaxo Group Ltd | Dominios variables sencillos de union de albumina anti-suero mejorados. |
| HUE051913T2 (hu) * | 2009-09-18 | 2021-04-28 | Codexis Inc | Csökkentett kodon mutagenezis |
| US20110082055A1 (en) * | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| EP2558112A4 (en) * | 2010-04-16 | 2014-06-18 | Medimmune Ltd | COMPOSITIONS AND METHODS OF TREATING THE CONTAINMENT OF A COPD |
| WO2012172070A1 (en) * | 2011-06-17 | 2012-12-20 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
| EP4350345A3 (en) | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| PL2723769T5 (pl) | 2011-06-23 | 2022-10-17 | Ablynx Nv | Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny |
| EP3363812A1 (en) | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| MY167125A (en) * | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| SG10201810124PA (en) | 2014-05-16 | 2018-12-28 | Ablynx Nv | Improved immunoglobulin variable domains |
| ES2900852T3 (es) | 2014-05-16 | 2022-03-18 | Ablynx Nv | Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| EP3374392B1 (en) | 2015-11-13 | 2021-11-24 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| EA038179B1 (ru) | 2015-11-18 | 2021-07-20 | Мерк Шарп И Доум Корп. | Ctla4-связывающие вещества |
| CA3005488A1 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| WO2017210749A1 (en) * | 2016-06-10 | 2017-12-14 | Adelaide Research & Innovation Pty Ltd | Methods and products for treating autoimmune diseases |
| ES2926014T3 (es) | 2016-06-23 | 2022-10-21 | Ablynx Nv | Ensayos farmacocinéticos mejorados para dominios variables individuales de inmunoglobulina |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| TW202323287A (zh) | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| RU2765384C2 (ru) | 2016-12-07 | 2022-01-28 | Аблинкс Нв | Улучшенные одиночные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| DK3571225T3 (da) | 2017-01-17 | 2024-11-04 | Ablynx Nv | Forbedrede serumalbuminbindere |
| BR112019014600A2 (pt) | 2017-01-17 | 2020-02-18 | Ablynx N.V. | Ligantes de albumina sérica melhorados |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| US12480957B2 (en) | 2017-03-31 | 2025-11-25 | Ablynx N.V. | Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs |
| MX2020005160A (es) | 2017-11-28 | 2020-08-20 | Chugai Pharmaceutical Co Ltd | Molecula de union a ligando que tiene actividad de union a ligando ajustable. |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| WO2019230866A1 (en) * | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
| CN109336977A (zh) * | 2018-10-11 | 2019-02-15 | 暨南大学 | 肿瘤干细胞标志分子EpCAM的结合蛋白及其应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US3907502A (en) * | 1973-12-11 | 1975-09-23 | Miless L Brink | Method for identifying Bence Jones proteins |
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US6511665B1 (en) * | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| WO1990005144A1 (en) * | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6451983B2 (en) * | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
| US5459061A (en) * | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| US5726152A (en) * | 1990-09-21 | 1998-03-10 | Merck & Co., Inc. | Vascular endothelial cell growth factor II |
| US5843440A (en) * | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
| CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
| OA10149A (en) * | 1991-03-29 | 1996-12-18 | Genentech Inc | Vascular endothelial cell growth factor antagonists |
| WO1993000917A1 (en) * | 1991-07-05 | 1993-01-21 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5770190A (en) * | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| WO1997014719A1 (en) * | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| US5664034A (en) * | 1996-05-21 | 1997-09-02 | Lucent Technologies Inc. | Lightwave communication monitoring switch |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| US6750044B1 (en) * | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| US20030165467A1 (en) * | 1997-01-21 | 2003-09-04 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6485942B1 (en) * | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6777534B1 (en) * | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
| US20020192211A1 (en) * | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US20030175271A1 (en) * | 1998-05-20 | 2003-09-18 | Kyowa Hakko Kogyo Co., Ltd. | VEGF activity inhibitor |
| US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE300957T1 (de) * | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| MXPA01010891A (es) * | 1999-04-28 | 2002-11-07 | Univ Texas | Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf). |
| US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
| HUP0201480A3 (en) * | 1999-05-14 | 2009-03-30 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| CA2373822A1 (en) * | 1999-05-20 | 2000-11-30 | Scios Inc. | Vascular endothelial growth factor variants |
| AU2001239884B2 (en) * | 2000-02-25 | 2006-08-10 | Vegenics Limited | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators |
| US20050019826A1 (en) * | 2000-03-31 | 2005-01-27 | Roselyne Tournaire | Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof |
| PT2857516T (pt) * | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US20030166524A1 (en) * | 2000-05-22 | 2003-09-04 | John Ford | Therapeutic uses of IL-1 receptor antagonist |
| EP1299419A2 (en) * | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| DE10038624C2 (de) * | 2000-08-03 | 2002-11-21 | Broekelmann Aluminium F W | Wärmeübertragungsrohr mit gedrallten Innenrippen |
| AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| SK14632003A3 (sk) * | 2001-05-08 | 2004-03-02 | Merck Patent Gmbh | Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel |
| RU2335507C2 (ru) * | 2001-06-13 | 2008-10-10 | Генмаб А/С | Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор |
| EP1399484B1 (en) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| CA2456236A1 (en) * | 2001-08-03 | 2003-02-20 | Commonwealth Scientific And Industrial Research Organisation | Methods of screening based on the egf receptor crystal structure |
| JP2005507659A (ja) * | 2001-10-15 | 2005-03-24 | イミューノメディクス、インコーポレイテッド | 直接ターゲッティング結合タンパク質 |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| EP1487879B1 (en) * | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| US7438910B2 (en) * | 2002-09-06 | 2008-10-21 | Amgen Inc. | Therapeutic human anti-IL1-R1 monoclonal antibody |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| EP3037105B1 (en) * | 2003-06-27 | 2021-03-17 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| CA2529819A1 (en) * | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| CA2533581C (en) * | 2003-07-24 | 2012-05-08 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050196340A1 (en) * | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| JP4906094B2 (ja) * | 2004-01-16 | 2012-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レセプターを活性化し得る融合ポリペプチド |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| KR20070086896A (ko) * | 2004-12-02 | 2007-08-27 | 도만티스 리미티드 | 항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도 |
-
2006
- 2006-11-30 AU AU2006321364A patent/AU2006321364B2/en not_active Expired - Fee Related
- 2006-11-30 KR KR1020087015994A patent/KR20080077238A/ko not_active Withdrawn
- 2006-11-30 BR BRPI0619225A patent/BRPI0619225A2/pt not_active IP Right Cessation
- 2006-11-30 US US12/085,920 patent/US20090155283A1/en not_active Abandoned
- 2006-11-30 TW TW095144416A patent/TW200730539A/zh unknown
- 2006-11-30 WO PCT/GB2006/004471 patent/WO2007063308A2/en not_active Ceased
- 2006-11-30 CA CA002632866A patent/CA2632866A1/en not_active Abandoned
- 2006-11-30 EA EA200801170A patent/EA200801170A1/ru unknown
- 2006-11-30 CN CNA2006800518832A patent/CN101454344A/zh active Pending
- 2006-11-30 EP EP06820376A patent/EP1957536A2/en not_active Withdrawn
- 2006-11-30 JP JP2008542829A patent/JP2009519011A/ja active Pending
-
2008
- 2008-05-15 NO NO20082215A patent/NO20082215L/no not_active Application Discontinuation
- 2008-05-27 CR CR10022A patent/CR10022A/es not_active Application Discontinuation
- 2008-06-02 MA MA30984A patent/MA30300B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519011A5 (enExample) | ||
| JP2009517069A5 (enExample) | ||
| JP2008521870A5 (enExample) | ||
| US11993639B2 (en) | Therapeutic IL-13 polypeptides | |
| JP2009518025A5 (enExample) | ||
| JP2008519813A5 (enExample) | ||
| RU2411957C2 (ru) | Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1 | |
| Izuhara et al. | IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies | |
| JP2009523460A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| JP2020505955A5 (enExample) | ||
| RU2007117196A (ru) | Лиганды, которые активируют эндогенные соединения | |
| JP2009518024A5 (enExample) | ||
| AU2012205384B2 (en) | IL-27 antagonists for treating inflammatory diseases | |
| JP2010500360A5 (enExample) | ||
| JP2008502366A5 (enExample) | ||
| US11472862B2 (en) | IL13Rα2 peptide and its uses | |
| AU2003220439A1 (en) | Methods for treating chronic obstructive pulmonary disease (copd) | |
| EP3068797A1 (en) | Epha3 and multi-valent targeting of tumors | |
| JP2016501837A (ja) | インターロイキン−６に対する抗体およびその使用 | |
| WO2018171405A1 (zh) | 一种选择性tnfr1拮抗肽sn10及其在炎症性肠病中的应用 | |
| JP2002538170A5 (enExample) | ||
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| AU2006209237B2 (en) | Use of BAFF to treat Th2-mediated conditions | |
| CN115698059A (zh) | 使用抗bet v 1抗体治疗过敏的方法 |